It is demonstrated that TLS, particularly Polη-dependent bypass, is a critical mechanism enabling replication fork rescue and survival under PARPi therapy, and targeting TLS provides a promising therapeutic strategy to augment PARPi efficacy and prevent resistance in BRCA-deficient ovarian cancer.
Abstract
Poly(ADP-ribose) polymerase inhibitors (PARPi) exploit synthetic lethality to treat BRCA1/2-mutated ovarian cancer, yet clinical responses are often incomplete and resistance frequently emerges. PARPi exert cytotoxic effects by inhibiting single-strand break repair and trapping PARP on DNA, which impedes replication fork progression and generates lethal double-strand breaks. However, tumor cells can mitigate these effects through activation of alternative DNA repair mechanisms. Here, we investigated the role of translesion synthesis (TLS), a DNA damage tolerance pathway in which specialized polymerases bypass DNA lesions to sustain replication, in mediating PARPi resistance using homologous recombination (HR)-deficient epithelial ovarian cancer cell lines, patient-derived organoids (PDOs), and orthotopic xenograft models. PARPi treatment markedly slowed replication fork progression and activated TLS. Genetic depletion of the TLS scaffold protein REV1 and TLS polymerase η (Polη, encoded by POLH) exacerbated olaparib-induced replication stress, impaired fork restart, and sensitized BRCA1/2-deficient cells to PARPi. Importantly, pharmacological TLS inhibition with JH-RE-06 synergized with olaparib to enhance cytotoxicity in HR-deficient cells and PDOs, while in vivo combination therapy delayed or prevented resistance and achieved sustained tumor regression. Notably, TLS blockade also suppressed the emergence of BRCA2 reversion mutations in BRCA2-mutated ovarian cancer cells and prevented the development of olaparib resistance during chronic olaparib exposure. Collectively, these findings demonstrate that TLS, particularly Polη-dependent bypass, is a critical mechanism enabling replication fork rescue and survival under PARPi therapy. Targeting TLS provides a promising therapeutic strategy to augment PARPi efficacy and prevent resistance in BRCA-deficient ovarian cancer.
A comparative framework for understanding resistance mechanisms and strategies to restore PARPi sensitivity in cancers with HRD is offered and strategies focusing on targeting repair mechanisms and replication stress signaling are discussed.
Kousalya Lavudi, M. Renjith, Charan Pithana Sai Venkata Vijay et al.· International Journal of Mol...· 0 citations
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) induce regressions and extend progression-free survival (PFS) in ovarian cancer, especially in tumors with BRCA1 or BRCA2 mutations that impair homologous recombination repair. While recent studies have clarified the key roles of BRCA1, BRCA2, and PARP1 in replicat...
A. Venkatachalam, Annabella R. Strathman, Xia Hou et al.· Signal Transduction and Targ...· 0 citations
Poly(ADP-ribose) polymerase inhibitors (PARPi) exploit homologous recombination (HR) deficiency in BRCA1/2-mutant cancers to induce synthetic lethality. PARPi also kill ataxia telangiectasia-mutated (ATM)-deficient cells, but the underlying mechanism has remained unclear. Here, we define the mechanism of PARPi cytotoxi...
Lucia Sommerova, Ashleigh King, J. Chapman· Molecules and Cells· 0 citations
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment landscape of breast cancer susceptibility gene (
BRCA
) mutant tumors by exploiting synthetic lethality arising from homologous recombination (HR) deficiency. Yet, a substantial proportion of solid tumors remain HR-proficient and thu...
Xiao-Yan Liu, Zhang-Xian Zhou, Yu-Han Guo et al.· Cell Death & Disease· 0 citations
Platinum and poly (ADP-ribose) polymerase (PARP) inhibitors are cornerstone therapies for ovarian cancer (OC), and their efficacy relies on homologous recombination deficiency (HRD), leaving more than 50% of HRD-negative OC patients with limited treatment options. This study investigated the epigenetic regulator, Pol...
Wen-Wen Wang, Lin Huang, Zheng Wei et al.· Cell Death & Disease· 0 citations